ERBB2 and breast cancer: 1,092 breast cancer patients were classified into five groups according the clinicopathological parameters provided by TCGA, including 30 Her2+_HR- patients, 59 Her2+_HR+ patients, 426 Luminal type (Her2-_HR+) patients, 97 triple negative (Tri-negative) patients, and 480 unknown patients (Table 1).